- AI models outperform physicians on cancer report summaries: Study
- St. Luke’s CFO joins RCM company’s advisory board
- Stanford names chief ambulatory officer
- 52 DSOs to know: 2026
- 10 hospitals, health systems looking for CFOs
- 10 hospitals, health systems looking for CFOs
- North Carolina system names CEO
- New Mexico hospital names CEO
- Hartford HealthCare launches patient AI tool in EHR
- What health questions are people asking Microsoft Copilot?
- The best states for physicians in the last 5 years
- Weill Cornell taps critical care, pulmonary chief
- UnityPoint Health market chief medical officer to retire
- 10 health system rating downgrades
- North Star’s restructuring moves forward
- Illinois hospital pauses patient care amid payroll challenges
- What the Best-Performing Revenue Cycles Have in Common
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- California peer-run behavioral health center to close amid funding shift
- ‘Integration only works if data lives in the same system’: How 5 systems are operationalizing behavioral health
- Medicaid work requirements could shrink enrollment by up to 10 million people in any given month
- Inside UHS’ playbook for responsible behavioral health growth
- Epic4 Specialty Partners adds Illinois practice
- Adventist Health cuts operating loss in 2025
- 10 surgeons making headlines in 1 month
- ‘Burning the candle from both ends’: New York hospital CFO on rising costs, revenue cuts
- ASCs are not hospitals — and 1 administrator says the industry is forgetting that
- The unsolved problems still plaguing dentistry
- American Dental Association adds mental health, GLP-1 prompts to patient forms
- 21 revenue cycle executive moves in 2026
- ASCA backs outpatient surgery access bill
- The outpatient explosion is here—can real estate keep up?
- North Carolina orthodontic practice opens 7th location
- The health systems with the top supply chain operations and 4 more updates
- Intuitive Surgical eyes ASCs as robotics’ next frontier
- Feds give first-ever green light to ASC estate planning ownership model
- Virginia hospital boosts workplace safety reporting 245% with 3 strategic shifts
- What’s next for Optum?
- The 47 rural emergency hospitals, by state
- ADA urges CMS to proceed with adult dental coverage expansion
- Where anesthesiology residents are headed: 2026 Match data by state
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- Imagen Dental Partners adds Washington practice
- Imagen Dental Partners appoints senior VP of M&A
- Arkansas man charged with making terroristic threats to dental office staff
- Smile Partners appoints DSO veteran as COO
- Financial challenges slam dental offices: 4 updates
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Scaling patient access the right way: The Stella-Nanonets blueprint
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- CMS unveils new pediatric care model
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Two-thirds of pediatric mental health triage scores inaccurate: Study
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Idaho lawmakers push to restore mental health programs
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- New York launches mental health training for first responder clinicians
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
- Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep
- ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode
- Alcohol Prep Pads Recalled Over Bacteria Risk, Cardinal Health Says
- Fewer patients traveled for abortions in 2025 as telehealth care increased, report finds
- Cologuard campaign reunites ‘Full House’ stars to give ‘The Talk’ about colon cancer screening
- Lilly to remove certain insulin products from European markets by 2027
- Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis
- Study Warns Fluoride Bans May Raise Tooth Decay in Children
- WuXi Bio's record number of new projects in 2025 leaned heavily on US clients
- “Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
- Gilead inks Manta pact to dive deeper into cancer patient support
- Cheap Children's Clothing Tainted With Lead, Study Says
- Insulin Prices Fell For Medicare Patients Under Biden-Era Caps, Study Finds
- New Fathers Face Mental Health Challenges, Study Finds
- Your Choice Of Booze Influences Your Risk Of Death, Study Says
- AI Gets a 'D' When Judging Scientific, Medical Claims
- New Online Tool Helps Parkinson's Patients Weigh Brain Implant Decision
- AI chatbot use for health information up 16% from 2024: Rock Health survey
- ‘They Tricked Me’: A Father Was Chained After He Went to ICE To Reunite With His Kids
- Wilmington PharmaTech commits $50M to US API expansion
- Strides recalls nearly 90K bottles of children's ibuprofen after contamination complaints
- Trump administration unveils national policy framework for AI as it moves to override state laws
- Breast Cancer Locator System Submitted for De Novo 510(k) by Cairn Surgical
- Breast Cancer Locator System Submitted for De Novo 510(k) by Cairn Surgical
- 17 spine surgery firsts in Q1
- 17 spine surgery firsts in Q1
- Cencora acquiring EyeSouth Partners' retina business for $1.1B
- Aunque tengas seguro dental, la factura puede ser muy alta
- Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order
- A look at how Optum Rx is using AI to address pharmacy fraud, waste and abuse
- AbbVie steps up to the plate as official pharma sponsor of MLB
- Gilead CEO Daniel O'Day nets $28.4M pay package as security and travel costs top $2M
- Nursing Homes Accused of False Diagnoses To Hide Drug Use
- FDA Approves Higher-Dose Wegovy To Help People Lose More Weight
- Teens Often Pressured To Send Sexual Photos by Someone They Know, Study Finds
- CommonSpirit, Humana reach 3-year national network agreement
- Match Day 2026: Growth in emergency medicine, psychiatry
- Nearly 90,000 Bottles of Children’s Ibuprofen Recalled Nationwide
- FTC launches multi-bureau Healthcare Task Force to spot 'new priority areas for enforcement'
- Algunos adultos de mediana edad deciden posponer la atención médica hasta tener Medicare
- ¿Qué tan bajo se puede llegar? Las cambiantes guías para el control de la presión arterial
- EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race
- Rural hospitals could apply for temporary interest-free construction, renovation loans under new bipartisan bill
- Rural Residents Have Highest Cancer Death Rates, Researchers Say
- Your Bank Account Might Show How Well Your Brain Will Age, Researchers Say
- Insurance Lapses Play Havoc With Diabetes Management, Study Shows
- Psychedelics Aren't Better Than Antidepressants In Treating Depression, Review Concludes
- A Nasal Swab for Alzheimer's? Duke Team Has One in Testing
- Heat Advisories Might Not Trigger Soon Enough For Some Seniors, Study Finds
- Don't Forget This: Study Shows Cannabis Exacts a Toll on Your Memory
- Want To Stress Less? Start With These Everyday Habits
- Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
- Remarks at The SEC Speaks in 2026: From Kitchen Table to Cap Table—Making Capital Formation Work for Small Businesses
- Health system AI adoption surges in 2026 with execs reporting increased ROI: survey
- Heart Benefits From GLP-1 Drugs Fade After Stopping, Study Finds
- Survey Shows More People Struggling To Afford ACA Insurance
- Up to 155,000 COVID Deaths May Not Have Been Counted, Study Finds
- FDA Drops Plan To Ban Tanning Beds for Minors Nationwide
- Mindray North America Enters Ventilator Market
- Mindray North America Enters Ventilator Market
Child deaths from marijuana ingestion increase after each state legalization. Packaging marijuana edibles like popular foot items sure doesn't help.
Commission demands firms immediately change unfair and deceptive packaging
July 5, 2023
As part of its ongoing monitoring of health-related advertising claims, the Federal Trade Commission today sent cease and desist letters – jointly with the U.S. Food and Drug Administration (FDA) – to six companies currently marketing edible products containing Delta-8 tetrahydrocannabinol (THC) in packaging that is almost identical to many snacks and candy children eat, including Doritos tortilla chips, Cheetos cheese-flavored snacks, and Nerds candy.
“Marketing edible THC products that can be easily mistaken by children for regular foods is reckless and illegal,” said Samuel Levine, Director of the FTC’s Bureau of Consumer Protection. “Companies must ensure that their products are marketed safely and responsibly, especially when it comes to protecting the well-being of children.”
“Children are more vulnerable than adults to the effects of THC, with many who have been sickened and even hospitalized after eating ‘edibles’ containing it. That’s why we’re issuing warnings to several companies selling copycat food products containing delta-8 THC, which can be easily mistaken for popular foods that are appealing to children and can make it easy for a young child to ingest in very high doses without realizing it,” said Janet Woodcock, M.D., Principal Deputy Commissioner, FDA.
The agencies sent letters to the following companies: 1) Delta Munchies LLC (Los Angeles, California); 2) Exclusive Hemp Farms (Gilroy, California) and Etienne-DuBois, LLC/Oshipt (Henrico, Virginia); 3) North Carolina Hemp Exchange, LLC, dba NC Hemp Shoppe (Raleigh, North Carolina; 4) Dr. Smoke, LLC, aka Dr. S, LLC (Kansas City, Missouri); 5) Nikte's Wholesale, LLC (Albuquerque, New Mexico); and 6) The Haunted Vapor Room (Franklin, New Jersey).
According to the letters, after reviewing online marketing for Delta-8 THC products sold by the six companies, the FTC has determined that their advertising may violate Section 5 of the FTC Act, which prohibits unfair or deceptive acts in or affecting commerce, including practices that present unwarranted health or safety risks. The letters stress that preventing practices that present such risks, particularly to children, is one of the Commission’s highest priorities, and that imitating non-THC-containing food products that children consume is misleading.
The companies’ Delta-8 THC products mimic a range of food that appeal to children. Dr. Smoke, LLC, for example, sells THC-infused “Doritos” that are marketed in packaging that is nearly the same as that of Doritos Nacho Cheese Flavored Tortilla Chips (see graphic), including using the same red background, the use of the Doritos name and triangle logo, and the depiction of two tortilla chips in the same position. In addition, Dr. Smoke’s THC-infused “Cheetos” are sold in packaging that is nearly identical to that of Cheetos Crunchy Flamin’ Hot Cheese Flavored Snacks, right down to the use of the Chester Cheetah mascot.
Another company, The Haunted Vapor Room, sells Delta-8 THC products called Rope 500mg Delta-8 Nerds Candy and Medicated Dope Rope Bites (see graphic) that closely resemble Nerds Rope candy, with both comprising multi-colored crunchy candies attached to a gummy rope, and packaging for the former using what appears to be the Nerds candy mascot.
A third company, Delta Munchies, LLC, markets Delta-8 THC gummies that look like conventional gummy candies that are often consumed by children (see graphic). The brightly colored packaging includes images of the products in fruity and sour flavors that the FTC contends enhance their appeal to children and increases the likelihood that they will mistakenly eat them, thinking they are traditional gummy candies.
In the letters, the FTC demands the companies stop marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to appeal to young children. The FTC also strongly encourages the sellers to review all of their marketing and product packaging for similar edible THC products, and to take swift action and steps to protect consumers, especially young children, from these products.
Finally, the FTC has asked each company to contact agency staff within 15 days to detail the specific actions it has taken to address the Commission’s concerns. The primary staff attorney on this matter is Christine DeLorme in the FTC’s Bureau of Consumer Protection.
Colorful graphics for specific products are shown in article photos.
Published yesterday by the Annals of Internal Medicine, a response to one of the pre-legalization claims: that medical marijuana access would help chronic pain patients transition from standard pain medications.
The article is eligible for CME Point-of-Care and MOC credits.
Full research accessible from the summary page: https://doi.org/10.7326/M23-0053
Original Research | 4 July 2023By Emma E. McGinty, PhD, Kayla N. Tormohlen, PhD, Nicholas J. Seewald, PhD, Mark C. Bicket, MD, PhD, Alexander D. McCourt, JD, PhD, Lainie Rutkow, JD, PhD, Sarah A. White, MS, and Elizabeth A. Stuart, PhDEffects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain
Abstract
Background:
State medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place of prescription opioid or clinical guideline–concordant nonopioid prescription pain medications or procedures.
Objective:
To assess effects of state medical cannabis laws on receipt of prescription opioids, nonopioid prescription pain medications, and procedures for chronic noncancer pain.
Design:
Using data from 12 states that implemented medical cannabis laws and 17 comparison states, augmented synthetic control analyses estimated laws’ effects on receipt of chronic noncancer pain treatment, relative to predicted treatment receipt in the absence of the law.
Setting:
United States, 2010 to 2022.
Participants:
583 820 commercially insured adults with chronic noncancer pain.
Measurements:
Proportion of patients receiving any opioid prescription, nonopioid prescription pain medication, or procedure for chronic noncancer pain; volume of each treatment type; and mean days’ supply and mean morphine milligram equivalents per day of prescribed opioids, per patient in a given month.
Results:
In a given month during the first 3 years of law implementation, medical cannabis laws led to an average difference of 0.05 percentage points (95% CI, −0.12 to 0.21 percentage points), 0.05 percentage points (CI, −0.13 to 0.23 percentage points), and −0.17 percentage points (CI, −0.42 to 0.08 percentage points) in the proportion of patients receiving any opioid prescription, any nonopioid prescription pain medication, or any chronic pain procedure, respectively, relative to what we predict would have happened in that month had the law not been implemented.
Limitations:
This study used a strong nonexperimental design but relies on untestable assumptions involving parallel counterfactual trends. Statistical power is limited by the finite number of states. Results may not generalize to noncommercially insured populations.
Conclusion:
This study did not identify important effects of medical cannabis laws on receipt of opioid or nonopioid pain treatment among patients with chronic noncancer pain.
Primary Funding Source:
National Institute on Drug Abuse.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.

















